Source comparison
Sermorelin vs Tesamorelin + Ipamorelin: Research Protocol Comparison
Mechanism GHRH receptor agonist (bioidentical GHRH 1-29) Dual-axis: GHRH analog + ghrelin mimetic Sermorelin works within natural pulsatile rhythms; blend overrides baseline signaling Blend delivers 2.5–3× higher peak GH levels Half-Life 10–20 minutes Tesamore
This comparison does not assign a generated winner or score.
- Mechanism
- GHRH receptor agonist (bioidentical GHRH 1-29)
- Dual-axis: GHRH analog + ghrelin mimetic
- Sermorelin works within natural pulsatile rhythms; blend overrides baseline signaling
- Blend delivers 2.5–3× higher peak GH levels
- Half-Life
- 10–20 minutes
- Tesamorelin 26–38 min; Ipamorelin ~2 hours
- Sermorelin requires precise timing; blend sustains elevation longer
- Blend offers more forgiving dosing windows
- Visceral Fat Reduction
- Minimal (no significant VAT reduction in trials)
- 15–20% VAT reduction at 26 weeks (FDA-approved for lipodystrophy)
- Tesamorelin specifically targets abdominal adiposity
- Blend wins decisively for metabolic endpoints
- Insulin Sensitivity
- Indirect (via GH normalization)
- Direct improvement via ghrelin pathways (18% fasting insulin reduction)
- Ipamorelin component influences HOMA-IR and glucose handling
- Blend superior for metabolic syndrome models
- Cost per 12-Week Protocol
- $240–$360
- $480–$720
- Sermorelin 40–60% less expensive
- Sermorelin wins on budget; blend wins on outcomes
- Receptor Desensitization Risk
- Low (mimics natural signaling)
- Moderate (dual-pathway stimulation may require cycling)
- Continuous GHRH stimulation can downregulate receptors over time
- Sermorelin safer for indefinite protocols